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Bio-Medical
This innovation uses partially misci-
ble fluids to form nano- and micro-
droplets in a microfluidic droplet gen-
erator system.
Droplet generators fabricated in
PDMS (polydimethylsiloxane) are cur-
rently being used to fabricate engi-
neered nanoparticles and microparti-
cles. These droplet generators were first
demonstrated in a T-junction configura-
tion, followed by a cross-flow configura-
tion. All of these generating devices have
used immiscible fluids, such as oil and
water. This immiscible fluid system can
produce mono-dispersed distributions
of droplets and articles with sizes rang-
ing from a few hundred nanometers to a
few hundred microns. For applications
such as drug delivery, the ability to en-
capsulate aqueous solutions of drugs
within particles formed from the
droplets is desirable.
Of particular interest are non-polar
solvents that can dissolve lipids for the
formation of liposomes in the droplet
generators. Such fluids include ether,
cyclohexane, butanol, and ethyl ac-
etate. Ethyl acetate is of particular inter-
est for two reasons. It is relatively non-
toxic and it is formed from ether and
acetic acid, and maybe broken down
into its constituents at relatively low
concentrations.
Further investigation of the liposome
properties reveals that optimal lipo-
some-forming mixtures have sufficient
density and viscosity to form droplets,
but also have the potential to be ex-
changed from aqueous solutions. Over-
all, ethyl acetate was found to be about
8 percent miscible in water, which sug-
gests that it could eventually be ex-
changed into a buffer solution. Based
on this solubility for ethyl acetate in
water, it was hypothesized that this mix-
ture of reagents was sufficiently immis-
cible to form droplets on the device.
Also, the PDMS droplet generator de-
vices were sufficiently resistant to the
solvent effects of ethyl acetate and re-
mained stable during the liposome-
forming process.
The fluidic system looks very much
like other solvent/water systems.
Droplets in the range of 100 to 5,000 nm
in diameter may be formed by adjusting
the flow rates. Liposomes were success-
fully fabricated in the ethyl acetate/
water system using various lipid mix-
tures. The liposomes were formed by dis-
solving a lipid mixture in ethyl acetate,
and producing droplets, in the droplet
generator. After droplet formation, the
droplets flowed from an outlet and were
dried down in a collection tube. This
demonstrated the advantage of the
droplet fluid system when the solvent
phase has a high vapor pressure. After
dry-down, the liposomes could then be
rehydrated into an aqueous (buffer) so-
lution for further use.
By way of contrast, a major limitation
to the immiscible fluid system is the fact
that the nanodroplets form an oil/water
emulsion when aqueous droplets are
formed in oil. In the case of nano- and
micro-particle formation from the
droplets, it is very difficult to separate
out the target particles from the oil in
the emulsion. Thus, it was desirable to
demonstrate an alternative solvent sys-
tem from which the particles can be
more readily separated.
This work was done by Donald Ackley and
Anita Forster of Nanotrope Inc. for Johnson
Space Center. For further information, contact
the JSC Innovation Partnerships Office at
(281) 483-3809. 
In accordance with Public Law 96-517,
the contractor has elected to retain title to this
invention. Inquiries concerning rights for its




Phone No.: (760) 942-0301
Refer to MSC-24082-1, volume and num-
ber of this NASA Tech Briefs issue, and the
page number.
Method and Apparatus for Forming Nanodroplets
This technique can create functionalized particles for targeted drug delivery.
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Varicella zoster virus (VZV) causes
chicken pox on first exposure (usually in
children), and reactivates from latency
causing shingles (usually in adults). Shin-
gles can be extremely painful, causing
nerve damage, organ damage, and blind-
ness in some cases. The virus can be life-
threatening in immune-compromised in-
dividuals. The virus is very difficult to
culture for diagnosis, requiring a week or
longer.
This invention is a rapid test for VZV
from a saliva sample and can be per-
formed in a doctor’s office. The kit is
small, compact, and lightweight.
Detec tion is sensitive, specific, and
noninvasive (no needles); only a saliva
sample is required. The test provides
results in minutes. The entire test is
performed in a closed system, with no
exposure to infectious materials. The
components are made mostly of inex-
pensive plastic injection molded parts,
many of which can be purchased off
the shelf and merely assembled. All bi-
ological waste is contained for fast, ef-
ficient disposal.
This innovation was made possible be-
cause of discovery of a NASA scientists’
flight experiment showing the presence
of VZV in saliva during high stress peri-
ods and disease. This finding enables cli-
nicians to quickly screen patients for
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VZV and treat the ones that show posi-
tive results with antiviral medicines. This
promotes a rapid recovery, easing of
pain and symptoms, and reduces
chances of complications from zoster.
Screening of high-risk patients
could be incorporated as part of a reg-
ular physical exam. These patients in-
clude the elderly, pregnant women,
and immune-compromised individu-
als. In these patients, VZV can be a life-
threatening disease. In both high- and
low-risk patients, early detection and
treatment with antiviral drugs can dra-
matically decrease or even eliminate
the clinical manifestation of disease.
This work was done by Duane L. Pierson of
Johnson Space Center; Satish K. Mehta of
EASI; Randall J. Cohrs and Don H. Gilden
of the University of Colorado Health Science
Center; and Robert E. Harding, independent
consultant. Inquiries concerning rights for the
commercial use of this invention should be ad-
dressed to David Poticha at the University of
Colorado, david.poticha@cu.edu. Refer to
MSC-24451-1.
Improved devices have been pro-
posed for collecting sweat for biochemi-
cal analysis — especially for determina-
tion of the concentration of Ca2+ ions in
sweat as a measure of loss of Ca from
bones. Unlike commercially available
sweat-collection patches used previously
in monitoring osteoporosis and in qual-
itative screening for some drugs, the
proposed devices would not allow evap-
oration of the volatile chemical compo-
nents (mostly water) of sweat. Moreover,
the proposed devices would be designed
to enable determination of the volumes
of collected sweat. From these volumes
and the quantities of Ca2+ and/or other
analytes as determined by other means
summarized below, one could deter-
mine the concentrations of the analytes
in sweat.
A device according to the proposal
would be flexible and would be worn
like a commercial sweat-collection
patch. It would be made of molded poly-
dimethylsiloxane (silicone rubber) or
other suitable material having proper-
ties that, for the purpose of analyzing
sweat, are similar to those of glass. The
die for molding the silicone rubber
would be fabricated by a combination of
lithography and electroplating. The die
would reproducibly form, in the silicone
rubber, a precisely defined number of
capillary channels per unit area, each
channel having a precisely defined vol-
ume. Optionally, electrodes for measur-
ing the Ca2+ content of the sweat could
be incorporated into the device. 
The volume of sweat collected in the
capillary channels of the device would
be determined from (1) the amount of
light or radio waves of a given wave-
length absorbed by the device and (2)
the known geometry of the array of cap-
illary channels. Then, in one of two op-
tions, centrifugation would be per-
formed to move the sweat from the
capillary tubes to the region containing
the electrodes, which would be used to
measure the Ca2+ content by a standard
technique. In the other option, centrifu-
gation would be performed to remove
the sweat from the device to make the
sweat available to other analytical instru-
ments for measuring concentrations of
substances other than Ca2+.
This work was done by Daniel L. Feeback of
Johnson Space Center and Mark S. F. Clarke of
the University of Houston. Further information
is contained in a TSP (see page 1).
In accordance with Public Law 96-517, the
contractor has elected to retain title to this inven-
tion. Inquiries concerning rights for its commer-
cial use should be addressed to:
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Improved Devices for Collecting Sweat for Chemical Analysis
Unlike prior devices, these would enable measurement of volumes of specimens.
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